CN102048952B - Chinese medicinal preparation for treating benign postatic hyperplasia - Google Patents
Chinese medicinal preparation for treating benign postatic hyperplasia Download PDFInfo
- Publication number
- CN102048952B CN102048952B CN2009102303012A CN200910230301A CN102048952B CN 102048952 B CN102048952 B CN 102048952B CN 2009102303012 A CN2009102303012 A CN 2009102303012A CN 200910230301 A CN200910230301 A CN 200910230301A CN 102048952 B CN102048952 B CN 102048952B
- Authority
- CN
- China
- Prior art keywords
- parts
- grams
- radix
- patients
- medicinal preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 17
- 206010020718 hyperplasia Diseases 0.000 title abstract description 6
- 239000002994 raw material Substances 0.000 claims abstract description 10
- 235000011201 Ginkgo Nutrition 0.000 claims abstract description 8
- 235000008100 Ginkgo biloba Nutrition 0.000 claims abstract description 8
- 239000004863 Frankincense Substances 0.000 claims abstract description 7
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 claims abstract description 6
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 claims description 19
- 208000004403 Prostatic Hyperplasia Diseases 0.000 claims description 18
- 239000003814 drug Substances 0.000 claims description 18
- 210000000582 semen Anatomy 0.000 claims description 15
- 238000001914 filtration Methods 0.000 claims description 10
- 241000717739 Boswellia sacra Species 0.000 claims description 8
- 241001057584 Myrrha Species 0.000 claims description 8
- 241001250596 Pleione Species 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 7
- 241000218628 Ginkgo Species 0.000 claims description 5
- 239000000706 filtrate Substances 0.000 claims description 5
- 241000592346 Ginkgophyta Species 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 8
- REPVLJRCJUVQFA-UHFFFAOYSA-N (-)-isopinocampheol Natural products C1C(O)C(C)C2C(C)(C)C1C2 REPVLJRCJUVQFA-UHFFFAOYSA-N 0.000 abstract 1
- MFYSUUPKMDJYPF-UHFFFAOYSA-N 2-[(4-methyl-2-nitrophenyl)diazenyl]-3-oxo-n-phenylbutanamide Chemical compound C=1C=CC=CC=1NC(=O)C(C(=O)C)N=NC1=CC=C(C)C=C1[N+]([O-])=O MFYSUUPKMDJYPF-UHFFFAOYSA-N 0.000 abstract 1
- 240000002234 Allium sativum Species 0.000 abstract 1
- 241000213006 Angelica dahurica Species 0.000 abstract 1
- 241000205585 Aquilegia canadensis Species 0.000 abstract 1
- 235000010894 Artemisia argyi Nutrition 0.000 abstract 1
- 235000003717 Boswellia sacra Nutrition 0.000 abstract 1
- 240000007551 Boswellia serrata Species 0.000 abstract 1
- 235000012035 Boswellia serrata Nutrition 0.000 abstract 1
- 240000007311 Commiphora myrrha Species 0.000 abstract 1
- 235000006965 Commiphora myrrha Nutrition 0.000 abstract 1
- 244000194101 Ginkgo biloba Species 0.000 abstract 1
- 244000025221 Humulus lupulus Species 0.000 abstract 1
- 235000008694 Humulus lupulus Nutrition 0.000 abstract 1
- 235000007265 Myrrhis odorata Nutrition 0.000 abstract 1
- 244000299790 Rheum rhabarbarum Species 0.000 abstract 1
- 235000009411 Rheum rhabarbarum Nutrition 0.000 abstract 1
- 235000017276 Salvia Nutrition 0.000 abstract 1
- 240000007164 Salvia officinalis Species 0.000 abstract 1
- 241000219784 Sophora Species 0.000 abstract 1
- 244000178320 Vaccaria pyramidata Species 0.000 abstract 1
- 235000010587 Vaccaria pyramidata Nutrition 0.000 abstract 1
- 244000030166 artemisia Species 0.000 abstract 1
- 229940116229 borneol Drugs 0.000 abstract 1
- CKDOCTFBFTVPSN-UHFFFAOYSA-N borneol Natural products C1CC2(C)C(C)CC1C2(C)C CKDOCTFBFTVPSN-UHFFFAOYSA-N 0.000 abstract 1
- DTGKSKDOIYIVQL-UHFFFAOYSA-N dl-isoborneol Natural products C1CC2(C)C(O)CC1C2(C)C DTGKSKDOIYIVQL-UHFFFAOYSA-N 0.000 abstract 1
- 235000004611 garlic Nutrition 0.000 abstract 1
- 208000014674 injury Diseases 0.000 abstract 1
- 231100000331 toxic Toxicity 0.000 abstract 1
- 230000002588 toxic effect Effects 0.000 abstract 1
- 230000008733 trauma Effects 0.000 abstract 1
- 210000002307 prostate Anatomy 0.000 description 11
- 210000003932 urinary bladder Anatomy 0.000 description 8
- 210000004907 gland Anatomy 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 4
- 229940079593 drug Drugs 0.000 description 3
- 239000000835 fiber Substances 0.000 description 3
- 230000002390 hyperplastic effect Effects 0.000 description 3
- 210000000664 rectum Anatomy 0.000 description 3
- 210000003462 vein Anatomy 0.000 description 3
- 206010003694 Atrophy Diseases 0.000 description 2
- 206010020880 Hypertrophy Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 210000000436 anus Anatomy 0.000 description 2
- 230000037444 atrophy Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 230000000762 glandular Effects 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 210000000244 kidney pelvis Anatomy 0.000 description 2
- 231100000957 no side effect Toxicity 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 230000010412 perfusion Effects 0.000 description 2
- 210000002706 plastid Anatomy 0.000 description 2
- 201000007094 prostatitis Diseases 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 210000000626 ureter Anatomy 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 208000037157 Azotemia Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 241000521257 Hydrops Species 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 206010046555 Urinary retention Diseases 0.000 description 1
- 210000002534 adenoid Anatomy 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 210000003484 anatomy Anatomy 0.000 description 1
- 210000000709 aorta Anatomy 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 206010005038 bladder diverticulum Diseases 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 208000019902 chronic diarrheal disease Diseases 0.000 description 1
- 208000013507 chronic prostatitis Diseases 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 230000001447 compensatory effect Effects 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 230000002607 hemopoietic effect Effects 0.000 description 1
- 208000014617 hemorrhoid Diseases 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 208000023958 prostate neoplasm Diseases 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000000700 radioactive tracer Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 210000004878 submucosal gland Anatomy 0.000 description 1
- 208000009852 uremia Diseases 0.000 description 1
- 210000003708 urethra Anatomy 0.000 description 1
- 210000001635 urinary tract Anatomy 0.000 description 1
- 208000019206 urinary tract infection Diseases 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a Chinese medicinal preparation for treating benign postatic hyperplasia, which is prepared from the following raw materials in part by weight: 10 to 20 parts of ginkgo seed, 10 to 20 parts of garlic, 10 to 15 parts of lightyellow sophora root, 5 to 15 parts of frankincense, 10 to 20 parts of grassleaf sweelflag rhizome, 10 to 30 parts of myrrh, 20 to 40 parts of root of red-rooted salvia, 10 to 20 parts of Chinese angelica, 5 to 8 parts of Chinese mugwort leaf, 5 to 20 parts of cowherb seed, 10 to 15 parts of rhizoma pleionis, 6 to 10 parts of liquoric root, 3 to 7 parts of rhubarb, 10 to 12 parts of honeysuckle bine and 4 to 6 parts of borneol. By the Chinese medicinal preparation, 240 patients who suffer from the benign postatic hyperplasia are treated, and 35 patients are cured; the Chinese medicinal preparation is significantly effective for 115 patients, effectual for 53 patients, and ineffective for 37 patients; and the total effective rate is 84.6 percent. The Chinese medicinal preparation has the advantages of obvious curative effect, no trauma, no toxic or side effect and the like.
Description
Technical field
The present invention relates to a kind of Chinese medicine preparation of treating prostatic hyperplasia.
Background technology
Prostatic hyperplasia is the common disease of Urology Surgery and andrology, and this type patient accounts for sizable ratio in urology department and andrology's outpatient service, inpatient, and its sickness rate is the trend that rises year by year in recent years.
The pathology of prostatic hyperplasia hyperplasia of prostate and analysis pathology: prostate is two-layer inside and outside dividing: internal layer is periurethral mucosa and submucosal gland body; Skin is a body of prostate.The latter constitutes prostatic main body, has fibrous membrane to separate between two-layer.The prostatic hyperplasia dictorial advisor mainly occurs in internal layer, behind one section of neck of bladder to seminal colliculus, in the gland plastid stroma of urethra, claims that at present this part is that the transitional zone microscopy is visible.The gland plastid stroma has slight hyperplastic tissue, and structure is main with outgrowth connective tissue and smooth muscle, and there have glandular sac, the hypertrophy glandular tube epithelium of increase to be mamillary to be outstanding in blister cavities, forms the Combination tuberosity of interstitial gland appearance tissue.Ratio according to a matter and adenoid tissue is different, and the many cases prostatic hyperplasia is divided into amphitypy, and the outgrowth outside compressing of fiber flesh type that fiber flesh gland type that tuberosity is big and soft and body of gland are little and hard makes outer field body of prostate become the pseudocapsule of skim fiber gland appearance gradually.Be prone to extract tuberosity so also claim gene surgery peplos on the clinical system in the film since then when being able to obvious boundary and mainly performing the operation because of itself and hypertrophy.
Outgrowth prostate blocks neck of bladder, and bladder is strengthened shrinking and made detrusor generation compensatory plumpness be girder shape projection for overcoming the cervical region resistance.Bladder cavity is intrinsic pressure to be increased, and mucous membrane of urinary bladder can outwards swell by weakness between muscle bundle, forms the diverticulum bladder neck and blocks.Continue to increase the weight of, urine will residue in bladder to some extent, follow increasing of residual urine, and wall of urinary bladder attenuation gradually makes ureter lower end diagonal pass the formed physiological flap valve of wall of urinary bladder flesh layer effect inefficacy.The intravesical urine is adverse current to ureter and renal pelvis just, causes urinary tract hydrops on the both sides, and renal pelvis is intrinsic pressure to be increased, and makes the atrophy of excess of the kidney matter ischemic, causes the renal function final uremia that takes place of going down.
At present, clinically, prostate is increased last shortage treat measure safely and effectively.
Summary of the invention
To above-mentioned prior art, the invention provides a kind of Chinese medicine preparation of treating prostatic hyperplasia, advantage such as have wound evident in efficacy, no, have no side effect.
The present invention realizes through following technical scheme:
A kind of Chinese medicine preparation of treating prostatic hyperplasia is to be processed by the raw material of following weight portion: 10～20 parts of Semen Ginkgoes, 10～20 parts in Bulbus Allii, 10～15 parts of Radix Sophorae Flavescentiss; 5～15 parts of Olibanums, 10～20 parts of Rhizoma Acori Graminei, 10～30 parts of Myrrhas, 20～40 parts of Radix Salviae Miltiorrhizaes; 10～20 parts of Radix Angelicae Sinensis, 5～8 parts of Folium Artemisiae Argyis, 5～20 parts of Semen Vaccariae, 10～15 parts of Pseudobulbus cremastrae seu pleiones; 6～10 parts in Radix Glycyrrhizae, 3～7 parts of Radix Et Rhizoma Rhei, 10～12 parts of Caulis Lonicerae, 4～6 parts of Borneolum Syntheticums.
Preferably, process: Semen Ginkgo 15 grams, Bulbus Allii 15 grams, Radix Sophorae Flavescentis 13 grams, Olibanum 10 grams, Rhizoma Acori Graminei 15 grams by following raw material; Myrrha 20 grams, Radix Salviae Miltiorrhizae 30 grams, Radix Angelicae Sinensis 15 grams, Folium Artemisiae Argyi 6 grams, Semen Vaccariae 13 grams; Pseudobulbus cremastrae seu pleiones 13 grams, Radix Glycyrrhizae 8 grams, Radix Et Rhizoma Rhei 5 grams, Caulis Lonicerae 11 grams, Borneolum Syntheticum 5 grams.
A kind of method for preparing of treating the Chinese medicine preparation of prostatic hyperplasia: after being ready to each raw material, decocting 40～60min filters, and must filtrate and filtering residue, and filtering residue is decocting 30～40min again, filters; Merge filtrating twice, promptly get.
During treatment, the patient takes RAR, and conduit is inserted 10～15cm in the anus, cleans enteric cavity with warm saline 100ml earlier, and the filtrating that will be heated to about 40 ℃ then slowly pours into.Perfusion keeps above-mentioned position 30min after accomplishing, and becomes dorsal position again and gets final product.Generally speaking, retention time is longer, and curative effect is better, but should keep 1h at least.This treatment every day 1 time, 30 days is a course of treatment, and general treatment is to be advisable 1～2 course of treatment.
Inventor of the present invention thinks: because the distinctive anatomical structure of prostate makes many medicines, the medicine of especially treating chronic prostatitis can't get into prostate and reach efficacious therapy concentration.Yet, profuse venous plexus is arranged around prostate and the rectum, this just provides necessary anatomical conditions for rectum absorbs the drug in this local formation high concentration gathering.People such as Shafik find that 2～6 little hemorrhoid vena genitalises are arranged between hemorrhoidal veins and the prostate vein, and these communicating branch oppositely do not transport the unidirectional urogenital venous plexus that is delivered to of the blood of hemorrhoidal veins.Simultaneously the woods of China Academy of TCM dies for a righteous cause and waits with the tracer method discovery, and the radioactivity of prostata tissue Chinese medicine all was higher than the radioactivity of ventral aorta Chinese medicine after the per rectum administration within 24 hours.Has one reasonability based on above these theoretical basiss and experimental result explanation rectally treatment prostatosis.
In the prescription of the present invention; Medicines such as Radix Salviae Miltiorrhizae, Olibanum, Myrrha, Pseudobulbus cremastrae seu pleiones, Semen Vaccariae can improve the partial microcirculation of prostate; Softening to a certain extent hyperplastic tissue makes progressively atrophy of hyperplastic prostate tissue, degeneration, thereby improves, alleviates a series of clinical symptoms that cause therefrom.
The present invention treats 240 routine prostatic hyperplasia patients altogether, cures 35 examples (14.6%), produce effects 115 examples (47.9%), effective 53 examples (22.1%), invalid 37 examples, total effective rate 84.6%.Advantage such as Chinese medicine preparation of the present invention has wound evident in efficacy, no, have no side effect.
The specific embodiment
Below in conjunction with embodiment and clinical data the present invention is further described:
1 one kinds of Chinese medicine preparation of treating prostatic hyperplasia of embodiment
Prescription is: Semen Ginkgo 10 grams, Bulbus Allii 20 grams, Radix Sophorae Flavescentis 10 grams, Olibanum 15 grams, Rhizoma Acori Graminei 10 grams, Myrrha 30 grams, Radix Salviae Miltiorrhizae 20 grams, Radix Angelicae Sinensis 20 grams, Folium Artemisiae Argyi 5 grams, Semen Vaccariae 20 grams, Pseudobulbus cremastrae seu pleiones 10 grams, Radix Glycyrrhizae 10 grams, Radix Et Rhizoma Rhei 3 grams, Caulis Lonicerae 12 grams, Borneolum Syntheticum 4 grams.
Method for preparing is: after being ready to each raw material, decocting 40min filters, and must filtrate and filtering residue, and filtering residue is decocting 40min again, filters; Merge filtrating twice, promptly get.
2 one kinds of Chinese medicine preparation of treating prostatic hyperplasia of embodiment
Prescription is: Semen Ginkgo 20 grams, Bulbus Allii 10 grams, Radix Sophorae Flavescentis 15 grams, Olibanum 5 grams, Rhizoma Acori Graminei 20 grams, Myrrha 10 grams, Radix Salviae Miltiorrhizae 40 grams, Radix Angelicae Sinensis 10 grams, Folium Artemisiae Argyi 8 grams, Semen Vaccariae 5 grams, Pseudobulbus cremastrae seu pleiones 15 grams, Radix Glycyrrhizae 6 grams, Radix Et Rhizoma Rhei 7 grams, Caulis Lonicerae 10 grams, Borneolum Syntheticum 6 grams.
Method for preparing is: after being ready to each raw material, decocting 60min filters, and must filtrate and filtering residue, and filtering residue is decocting 30min again, filters; Merge filtrating twice, promptly get.
3 one kinds of Chinese medicine preparation of treating prostatic hyperplasia of embodiment
Prescription is: Semen Ginkgo 15 grams, Bulbus Allii 15 grams, Radix Sophorae Flavescentis 13 grams, Olibanum 10 grams, Rhizoma Acori Graminei 15 grams, Myrrha 20 grams, Radix Salviae Miltiorrhizae 30 grams, Radix Angelicae Sinensis 15 grams, Folium Artemisiae Argyi 6 grams, Semen Vaccariae 13 grams, Pseudobulbus cremastrae seu pleiones 13 grams, Radix Glycyrrhizae 8 grams, Radix Et Rhizoma Rhei 5 grams, Caulis Lonicerae 11 grams, Borneolum Syntheticum 5 grams.
Method for preparing is: after being ready to each raw material, decocting 50min filters, and must filtrate and filtering residue, and filtering residue is decocting 35min again, filters; Merge filtrating twice, promptly get.
Clinical data:
Clinical data: prostatic hyperplasia patient 240 examples; Wherein (NIH scoring (CPSI) >=4 are divided into the standard of including in the state-run commune hospital of the U.S.; Get rid of tumor of prostate, acute prostatitis, lower urinary tract infection and chronic diarrhea patient, and get rid of the heart, liver, kidney and hemopoietic system serious disease patient.
Therapeutic Method: the patient takes RAR, and conduit is inserted 10～15cm in the anus, and earlier with warm saline 100ml cleaning enteric cavity, ((embodiment 3 is prepared) slowly pours into will to be heated to filtrating about 40 ℃ then.Perfusion keeps above-mentioned position 30min after accomplishing, and becomes dorsal position again, keeps 80min.Every day 1 time, 30 days is a course of treatment.After 30 days, curative effect is estimated.
Criterion of therapeutical effect: recovery from illness: the scoring of symptom degree reduces more than 90% before the treatment; Produce effects: the scoring of symptom degree reduces 60～89% before the treatment; Effectively: the scoring of symptom degree reduces 30～59% before the treatment; Invalid: the scoring of symptom degree reduces less than 30% before the treatment.
Therapeutic outcome: 240 routine prostatic hyperplasia patients, cure 35 examples (14.6%), produce effects 115 examples (47.9%), effective 53 examples (22.1%), invalid 37 examples, total effective rate 84.6%.
Claims (3)
1. the Chinese medicine preparation through rectally treatment prostatic hyperplasia is characterized in that, is to be processed by the raw material of following weight portion: 10～20 parts of Semen Ginkgoes, 10～20 parts in Bulbus Allii, 10～15 parts of Radix Sophorae Flavescentiss; 5～15 parts of Olibanums, 10～20 parts of Rhizoma Acori Graminei, 10～30 parts of Myrrhas, 20～40 parts of Radix Salviae Miltiorrhizaes; 10～20 parts of Radix Angelicae Sinensis, 5～8 parts of Folium Artemisiae Argyis, 5～20 parts of Semen Vaccariae, 10～15 parts of Pseudobulbus cremastrae seu pleiones; 6～10 parts in Radix Glycyrrhizae, 3～7 parts of Radix Et Rhizoma Rhei, 10～12 parts of Caulis Lonicerae, 4～6 parts of Borneolum Syntheticums.
2. a kind of Chinese medicine preparation through rectally treatment prostatic hyperplasia according to claim 1 is characterized in that, is processed by following raw material: Semen Ginkgo 15 grams, Bulbus Allii 15 grams, Radix Sophorae Flavescentis 13 grams; Olibanum 10 grams, Rhizoma Acori Graminei 15 grams, Myrrha 20 grams, Radix Salviae Miltiorrhizae 30 grams; Radix Angelicae Sinensis 15 grams, Folium Artemisiae Argyi 6 grams, Semen Vaccariae 13 grams, Pseudobulbus cremastrae seu pleiones 13 grams; Radix Glycyrrhizae 8 grams, Radix Et Rhizoma Rhei 5 grams, Caulis Lonicerae 11 grams, Borneolum Syntheticum 5 grams.
3. the described a kind of method for preparing of treating the Chinese medicine preparation of prostatic hyperplasia of claim 1 is characterized in that: after being ready to each raw material, decocting 40～60min filters, and must filtrate and filtering residue, and filtering residue is decocting 30～40min again, filters; Merge filtrating twice, promptly get.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2009102303012A CN102048952B (en) | 2009-11-09 | 2009-11-09 | Chinese medicinal preparation for treating benign postatic hyperplasia |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2009102303012A CN102048952B (en) | 2009-11-09 | 2009-11-09 | Chinese medicinal preparation for treating benign postatic hyperplasia |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102048952A CN102048952A (en) | 2011-05-11 |
| CN102048952B true CN102048952B (en) | 2012-04-18 |
Family
ID=43953969
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2009102303012A Expired - Fee Related CN102048952B (en) | 2009-11-09 | 2009-11-09 | Chinese medicinal preparation for treating benign postatic hyperplasia |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102048952B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102579754A (en) * | 2012-02-21 | 2012-07-18 | 简福川 | Chinese medicament for treating qi stagnation and blood stasis type prostatitis |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1753682A (en) * | 2003-01-16 | 2006-03-29 | 利盛私人有限公司 | The herbal-composition that is used for prostatosis |
-
2009
- 2009-11-09 CN CN2009102303012A patent/CN102048952B/en not_active Expired - Fee Related
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1753682A (en) * | 2003-01-16 | 2006-03-29 | 利盛私人有限公司 | The herbal-composition that is used for prostatosis |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102048952A (en) | 2011-05-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104523865A (en) | Medicine for treating breast diseases | |
| CN101020033B (en) | Medicine for treating renal calculus | |
| CN101780260B (en) | Traditional Chinese medicine decoction for treating gynecologic chronic pelvic pain | |
| CN102048952B (en) | Chinese medicinal preparation for treating benign postatic hyperplasia | |
| CN101732495A (en) | Preparation method of Chinese medicament for treating inflammatory external hemorrhoid | |
| CN102988788B (en) | Traditional Chinese medicine for treating chronic pelvic inflammatory disease and clysis nursing method | |
| CN104258362A (en) | Traditional Chinese medicine preparation for treating peripheral neuritis | |
| CN101879273B (en) | Medicament for treating cold by enema method | |
| CN102600272A (en) | Traditional Chinese medicine for treatment of orthopedic disease | |
| CN104667027A (en) | Traditional Chinese medicine liquor for treating prostatic hyperplasia and preparation method of traditional Chinese medicine liquor | |
| CN102626458A (en) | Urologic anti-inflammation pill | |
| CN102145150B (en) | Medicine for treatment of uninary calculi | |
| CN103330793B (en) | Traditional Chinese medicine enema for treating chronic pelvic inflammatory disease | |
| CN1299728C (en) | Capsules of Tokyo violet, dandelion and flavescent sophora root and their making method | |
| CN110251576A (en) | A kind of Chinese medicine composition and preparation for alleviating renal colic caused by nephrolith disease and decorporation | |
| CN103736014A (en) | Chinese medicinal composition for treating prostatic hyperplasia | |
| CN101167829B (en) | Traditional Chinese medicinal composition and enema for treating chronic colitis and preparation method thereof | |
| CN100371006C (en) | Chinese traditional medicine formula for curing cysticercosis | |
| CN102688456B (en) | Chinese medicinal composition for treating chronic prostatitis | |
| CN106822524B (en) | Compound medicine for treating infertility and preparation method and application thereof | |
| CN101618118B (en) | Application of Chinese medicinal composition in preparing medicament for treating cystitis | |
| CN104524059A (en) | Traditional Chinese medicinal enema for treating constipation after craniocerebral trauma | |
| CN104474457A (en) | Traditional Chinese medicine composition for externally applying to treat benign prostatic hyperplasia | |
| CN105770440A (en) | Traditional Chinese medicine preparation for treating cerebral concussion | |
| CN104398992A (en) | Traditional Chinese medicinal preparation for treating infectious trauma |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| ASS | Succession or assignment of patent right |
Owner name: CHEN LIHUI Free format text: FORMER OWNER: WANG JINGJING Effective date: 20111121 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| C53 | Correction of patent for invention or patent application | ||
| CB03 | Change of inventor or designer information |
Inventor after: Chen Lihui Inventor after: Zhang Yuanchao Inventor after: Meng Hongyan Inventor before: Wang Jingjing |
|
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 250014 JINAN, SHANDONG PROVINCE TO: 250000 JINAN, SHANDONG PROVINCE Free format text: CORRECT: INVENTOR; FROM: WANG JINGJING TO: CHEN LIHUI ZHANG YUANCHAO MENG HONGYAN |
|
| TA01 | Transfer of patent application right |
Effective date of registration: 20111121 Address after: 250000, 416, four, Shandong, Ji'nan Province, elegant classical District Applicant after: Chen Lihui Address before: 250014 No. 44 West Wenhua Road, Lixia District, Shandong, Ji'nan Applicant before: Wang Jingjing |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: SHANDONG PROVINCIAL HOSPITAL Effective date: 20120816 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 250000 JINAN, SHANDONG PROVINCE TO: 250021 JINAN, SHANDONG PROVINCE |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20120816 Address after: Huaiyin District of Ji'nan City, Shandong province 250021 five road No. 324 Patentee after: Shandong Provincial Hospital Address before: 250000, 416, four, Shandong, Ji'nan Province, elegant classical District Patentee before: Chen Lihui |
|
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20120418 Termination date: 20121109 |